Essential Of The U.S Health Care System

Takeda, Japan's biggest drugmaker, said on Friday that U.S. health authorities have not been able to complete a review of alogliptin or SYR-322, which is critical to Takeda's mainstay diabetes business as it is expected to be the main replacement for its best-selling Actos.

Actos generates almost 30 percent of Takeda's sales but loses U.S. patent protection in 2011.

More

This entry was posted on Friday, October 10th, 2008 at 10:02 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.